Stock TELA TELA BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings TELA Bio, Inc.

Equities

TELA

US8723811084

Market Closed - Nasdaq
Other stock markets
 01:30:00 30/04/2024 am IST 		5-day change 1st Jan Change
4.52 USD +1.57% Intraday chart for TELA Bio, Inc. -1.09% -31.72%
15/04 TELA Bio, Inc. Announces U.S. Commercial Launch of Robotic-Compatible OviTex IHR CI
22/03 Piper Sandler Adjusts Price Target on TELA Bio to $12 From $15, Maintains Overweight Rating MT

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Considering the small differences between the analysts' various estimates, the group's business visibility is good.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company has insufficient levels of profitability.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • For the last few months, analysts have been revising downwards their earnings forecast.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
TELA BIO, INC. Stock TELA Bio, Inc.
-31.72% 111M
C-
ABBOTT LABORATORIES Stock Abbott Laboratories
-2.54% 186B
C+
MEDTRONIC PLC Stock Medtronic plc
-1.85% 107B
C
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-4.26% 67.44B
A
DEXCOM, INC. Stock DexCom, Inc.
+1.39% 50.03B
B-
CENCORA, INC. Stock Cencora, Inc.
+16.82% 47.81B
B-
HOYA CORPORATION Stock Hoya Corporation
+4.79% 41.03B
B+
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+3.49% 26.85B
B
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
+0.65% 25.82B
A-
TERUMO CORPORATION Stock Terumo Corporation
+16.55% 24.74B
A-
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. TELA Stock
  4. Ratings TELA Bio, Inc.